Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $134.1 million.

  • Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.69% to $134.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.1 million, marking a year-over-year increase of 1.69%. This contributed to the annual value of $133.2 million for FY2024, which is 36.42% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $134.1 million, which was up 0.34% from $133.6 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $134.1 million during Q3 2025, with a 5-year trough of $94.0 million in Q1 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $113.3 million (2024), whereas its average is $116.4 million.
  • Data for Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 36.42% (in 2024) over the last 5 years.
  • Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $94.6 million in 2022, then grew by 3.21% to $97.6 million in 2023, then skyrocketed by 36.42% to $133.2 million in 2024, then grew by 1.69% to $134.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $134.1 million for Q3 2025, versus $133.6 million for Q2 2025 and $133.6 million for Q1 2025.